Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FKAT6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,798
Award facts
- Contract value 100% obligated
- $29,797.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $29,797.50 to DMS Pharmaceutical Group Inc. for 300 mg vials of Entyvio, a biologic immunosuppressant medication, with an ultimate completion date of February 2, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded this firm fixed-price delivery order without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The award was funded by the Defense Logistics Agency's Medical Supply Chain division to support Department of Defense healthcare operations.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $499.999 billion ceiling value and extends through December 31, 2036. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors capable of supplying comprehensive pharmaceutical products and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FKAT6?
SPE2DR26FKAT6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FKAT6 worth?
The government has obligated $29,798 on SPE2DR26FKAT6.
Is contract SPE2DR26FKAT6 an order under another contract?
Yes. SPE2DR26FKAT6 is a delivery order under SPE2DR25D9365, an indefinite delivery contract.
Was contract SPE2DR26FKAT6 competed?
The extent of competition for SPE2DR26FKAT6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award